Electromed Stock Z Score
| ELMD Stock | USD 16.73 0.34 2.07% |
Electromed | Z Score |
Electromed Company Z Score Analysis
Electromed's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Electromed Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Electromed is extremely important. It helps to project a fair market value of Electromed Stock properly, considering its historical fundamentals such as Z Score. Since Electromed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Electromed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Electromed's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Electromed has a Z Score of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Electromed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Electromed from analyzing Electromed's financial statements. These drivers represent accounts that assess Electromed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Electromed's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 129.3M | 96.7M | 81.7M | 90.6M | 81.6M | 85.7M | |
| Enterprise Value | 118.9M | 84.9M | 73.6M | 83.4M | 75.1M | 78.8M |
Electromed Fundamentals
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0721 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 124.97 M | ||||
| Shares Outstanding | 8.61 M | ||||
| Shares Owned By Insiders | 26.69 % | ||||
| Shares Owned By Institutions | 32.78 % | ||||
| Number Of Shares Shorted | 42.93 K | ||||
| Price To Earning | 23.66 X | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 2.42 X | ||||
| Revenue | 48.07 M | ||||
| Gross Profit | 36.52 M | ||||
| EBITDA | 4.62 M | ||||
| Net Income | 3.17 M | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 161 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 4.83 X | ||||
| Book Value Per Share | 4.69 X | ||||
| Cash Flow From Operations | 1.31 M | ||||
| Short Ratio | 1.06 X | ||||
| Earnings Per Share | 0.45 X | ||||
| Target Price | 26.0 | ||||
| Number Of Employees | 170 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 141.04 M | ||||
| Total Asset | 45.81 M | ||||
| Retained Earnings | 18.79 M | ||||
| Working Capital | 29.73 M | ||||
| Current Asset | 15.82 M | ||||
| Current Liabilities | 3.07 M | ||||
| Net Asset | 45.81 M |
About Electromed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Electromed's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Electromed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Electromed based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Electromed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Electromed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Electromed will appreciate offsetting losses from the drop in the long position's value.Moving together with Electromed Stock
| 0.76 | HQY | HealthEquity Financial Report 3rd of June 2024 | PairCorr |
Moving against Electromed Stock
| 0.71 | RSLS | ReShape Lifesciences | PairCorr |
| 0.68 | HSDT | Helius Medical Techn Financial Report 9th of May 2024 | PairCorr |
| 0.64 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
| 0.62 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
| 0.58 | SINT | SINTX Technologies | PairCorr |
The ability to find closely correlated positions to Electromed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Electromed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Electromed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Electromed to buy it.
The correlation of Electromed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Electromed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Electromed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Electromed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Electromed Piotroski F Score and Electromed Valuation analysis. For information on how to trade Electromed Stock refer to our How to Trade Electromed Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Electromed Stock analysis
When running Electromed's price analysis, check to measure Electromed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Electromed is operating at the current time. Most of Electromed's value examination focuses on studying past and present price action to predict the probability of Electromed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Electromed's price. Additionally, you may evaluate how the addition of Electromed to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Electromed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Electromed. If investors know Electromed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Electromed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.727 | Earnings Share 0.45 | Revenue Per Share 6.072 | Quarterly Revenue Growth 0.167 | Return On Assets 0.0721 |
The market value of Electromed is measured differently than its book value, which is the value of Electromed that is recorded on the company's balance sheet. Investors also form their own opinion of Electromed's value that differs from its market value or its book value, called intrinsic value, which is Electromed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Electromed's market value can be influenced by many factors that don't directly affect Electromed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Electromed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Electromed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Electromed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.